4 Undervalued Pharmaceuticals Stocks for Wednesday, November 06
Discover the top 4 undervalued Pharmaceuticals stocks for Wednesday, November 06 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jack Gilleland
Eunice Kim
Eunice Kim
| Share Statistics | UPC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.5 | $618.0 | 2% |
|
| Shares Out (Mil) | 0.6 | 44.8 | 3% |
|
| Institutional Ownership | 32.6% | 85.3% | 14% |
|
| Float (Mil) | 0.6 | 47.4 | 1% |
|
| Beta | 1.53 | 0.70 | 84% |
|
| Avg Daily Volume (000s) | 60 | 390 | 30% |
|
| Price Change (52-week) |
55.8% | 68.6% | 81% |
|
| Growth | UPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.2%) | 6.7% | 5% |
|
| Net Income (5yr) | (20.0%) | (1.6%) | 20% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | UPC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $291 | 12% |
|
| Net Income (TTM) (Mil) | ($2) | ($11) | 37% |
|
| EPS (TTM) | ($3.448) | ($0.700) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($6) | 19% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $5 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $6 | 20% |
|
| Enterprise Value (Q1) (Mil) | ($16) | $450 | 1% |
|
| Valuation | UPC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.05 | 2.78 | 1% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | UPC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 36.5% | 67.0% | 45% |
|
| Net Margin | (10.9%) | (2.3%) | 20% |
|
| ROA | (2.6%) | (22.4%) | 33% |
|
| ROE | (3.5%) | (20.2%) | 32% |
|
| Liabilities to Assets | 22.1% | 32.2% | 15% |
|
| F-Score | 4 | 3 | 34% |
|
Universe Pharmaceuticals INC did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors